LOGIN  |  REGISTER
Chimerix
Viking Therapeutics

Neogen Announces James Walter as Vice President, Global Operations

February 06, 2024 | Last Trade: US$13.07 0.09 0.69

LANSING, Mich., Feb. 6, 2024 /PRNewswire/ -- Neogen® Corporation (NASDAQ: NEOG) announced that the Company has appointed James Walter to the position of Vice President, Global Operations. In this role, Mr. Walter will lead and manage Neogen's global manufacturing and logistics functions.

Mr. Walter comes to Neogen after having spent most of his career at Mallinckrodt Pharmaceuticals and its predecessors, most recently as Executive Director of Manufacturing Excellence, focused on driving improvement in the company's specialty generics business and overall plant operations. Previously at Mallinckrodt, he worked in various operations disciplines, helping to execute a wide range of initiatives to drive operational improvement and integration activities, as well as support growth initiatives. Mr. Walter also spent several years in the clean energy industry as Senior Vice President of Operations and Engineering at Tinuum and served as the Vice President of Operations at Catalent Pharma Solutions, where he helped to stabilize and grow the company's oral and specialty delivery operations worldwide.

"We are excited to welcome Jim to Neogen and add his wealth of operational knowledge to our global leadership team," said John Adent, Neogen's President and CEO. "Jim brings a great deal of operations and supply chain excellence experience to the company, which will be a significant asset for us, particularly as we continue to integrate the former 3M Food Safety Division into our business."

Mr. Walter graduated with honors from the United States Naval Academy with a degree in mathematics and engineering, then served in the Navy as a nuclear engineer.

About Neogen

Neogen Corporation is committed to fueling a brighter future for global food security through the advancement of human and animal well-being. Harnessing the power of science and technology, Neogen has developed comprehensive solutions spanning the Food Safety, Livestock, and Pet Health & Wellness markets. A world leader in these fields, Neogen has a presence in over 140 countries with a dedicated network of scientists and technical experts focused on delivering optimized products and technology for its customers.

Contact

Bill Waelke | Vice President, Investor Relations and Treasury
This email address is being protected from spambots. You need JavaScript enabled to view it.

Assertio

Stock Quote

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page